Peptide
Cetrorelix (Cetrotide)
Cetrorelix is a synthetic decapeptide GnRH antagonist. FDA-approved in 1999 for IVF/ICSI to prevent premature LH surge. Available as 0.25mg (multiple dose) and 3mg (single dose). Phase 3 trials show ~100% prevention of premature LH surge. Clinical pregnancy rate 26.3%. Nearly 100% prevention of ovarian hyperstimulation syndrome. Currently gold standard for IVF protocols.
- Updated
- How we grade
- 45 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 1
- Outcomes
- 10
- Graded outcomes
- 4222
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- LH Surge PreventionImproves (the measure goes down)
- Clinical Pregnancy RateImproves (the measure goes up)
- OHSS PreventionChanges; see studies
Studies cited
45 studies from PubMed
- Effectiveness and safety of GnRH antagonist originator and generic in real-world clinical practice: a retrospective cohort study.
- Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds.
- Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.
- GnRH antagonist treatment of malignant adrenocortical tumors.
- Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial.
- Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial.
- Cetrorelix suppresses the preovulatory LH surge and ovulation induced by ovulation-inducing factor (OIF) present in llama seminal plasma.
- GnRH antagonist cetrorelix inhibits mitochondria-dependent apoptosis triggered by chemotherapy in granulosa cells of rats.
- A circadian egg timer gates ovulation.
- Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study.
- Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
- Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40.
- GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.
- Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial
- Effect of cetrorelix dose on premature LH surge during ovarian stimulation
- Cetrorelix suppression test in the diagnostic work-up of severe hyperandrogenism in adolescence.
- Serum cetrorelix concentrations do not affect clinical pregnancy outcome in assisted reproduction.
- Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
- Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
- Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
- Cetrorelix in the treatment of female infertility and endometriosis.
- Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies
- Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction
- Clinical outcomes of controlled ovarian hyperstimulation for IVF using cetrorelix: a European multicentre trial
- Extrapituitary effects of GnRH antagonists in assisted reproduction: a review.
- Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
- Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents?
- Pharmacokinetic/pharmacodynamic modeling of luteinizing hormone (LH) suppression and LH surge delay by cetrorelix after single and multiple doses in healthy premenopausal women
- Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
- No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols.
- Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences.
- Cetrorelix, a gonadotrophin-releasing hormone antagonist, for the treatment of endometriosis
- The place of gonadotrophin-releasing hormone antagonists in reproductive medicine.
- Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
- Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)
- The LHRH antagonist cetrorelix: a review.
- Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin.
- The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg
- A European multicentre study comparing the efficacy of cetrorelix in preventing premature LH surges in women undergoing assisted reproduction
- Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
- Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
- Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study
- The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program
- Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men.
- Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.